Show simple item record

dc.contributor.authorMora, Toni
dc.contributor.authorSánchez-Collado, Irene
dc.contributor.authorMuñoz‐Cano, Rosa
dc.contributor.authorRibó, Paula
dc.contributor.authorPalomo‐Jiménez, Paloma I.
dc.contributor.authorMullol, Joaquim
dc.contributor.authorValero, Antonio
dc.date.accessioned2024-12-16T10:48:26Z
dc.date.available2024-12-16T10:48:26Z
dc.date.issued2024
dc.identifier.citationMora, Toni; Sánchez-Collado, Irene; Muñoz‐Cano, Rosa [et al.]. Prevalence and coexistence of type 2 inflammatory diseases. Clinical and Translational Allergy, 2024, 14(6), e12376. Disponible en: <https://onlinelibrary.wiley.com/doi/10.1002/clt2.12376>. Fecha de acceso: 16 dic. 2024. DOI: 10.1002/clt2.12376ca
dc.identifier.issn2045-7022ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/4464
dc.descriptionSanofi; University of Catalonia Real‐WordEvidence Chair
dc.description.abstractBackground: Type 2 inflammation has been described as a pathophysiological basis common to some diseases, such as atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps, and asthma (CRSwNP). Objective: The present study used population-based prevalence in Catalonia to analyse the coexistence of type 2 inflammatory diseases in patients primarily diagnosed with the above mentioned conditions. Results: We found a high degree of coexistence of type 2 inflammatory diseases among these patients, with the prevalence being higher in the severe forms, except for AD. For the severe forms of primary diseases, the proportion of patients with coexisting type 2 inflammatory diseases (severe or non-severe) was 16.2% for AD, 19.8% for asthma, and a striking 62.4% for CRSwNP. This patient population has the highest proportion of coexisting type 2 inflammatory diseases, both severe (48.9%) and non-severe (13.5%). Conclusion: Our findings have significant implications for the management of patients with AD, asthma, and CRSwNP.ca
dc.format.extent4ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofClinical and Translational Allergyca
dc.relation.ispartofseries14;6
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-vided the original work is properly cited.© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.ca
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherMalalties inflamatòriesca
dc.subject.otherAsmaca
dc.subject.otherEstudi epidemiològicca
dc.subject.otherEnfermedades inflamatoriasca
dc.subject.otherAsmaca
dc.subject.otherEstudio epidemiológicoca
dc.subject.otherInflammatory diseasesca
dc.subject.otherAsthmaca
dc.subject.otherEpidemiological studyca
dc.titlePrevalence and coexistence of type 2 inflammatory diseasesca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.2ca
dc.identifier.doihttps://dx.doi.org/10.1002/clt2.12376ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-vided the original work is properly cited.© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint